Pliant Therapeutics (PLRX) Cash from Financing Activities (2019 - 2026)
Pliant Therapeutics (PLRX) reported Cash from Financing Activities of $74000.0 for Q1 2026, down 85.14% year-over-year from $498000.0 in Q1 2025, and up 100.23% quarter-over-quarter from -$32.3 million in Q4 2025.
Pliant Therapeutics (PLRX) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has 8 years of Cash from Financing Activities data on file, last reported at $74000.0 in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at $74000.0, down 85.14% year-over-year; the trailing twelve-month figure through Mar 2026 was -$32.1 million (down 1858.13% YoY), and the FY2025 annual result was -$31.7 million, down 237.12% from the prior year.
- Cash from Financing Activities advanced to $74000.0 in Q1 2026 per PLRX's latest filing, from -$32.3 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $273.3 million in Q1 2023 and troughed at -$32.3 million in Q4 2025.
- A 5-year average of $30.8 million and a median of $391000.0 in 2022 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities surged 178744.44% in 2023, then tumbled 31734.31% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at $284000.0 in 2022, then declined by 22.89% to $219000.0 in 2023, then slumped by 53.42% to $102000.0 in 2024, then plunged by 31734.31% to -$32.3 million in 2025, then jumped by 100.23% to $74000.0 in 2026.
- Business Quant data shows PLRX's Cash from Financing Activities at $74000.0 in Q1 2026, -$32.3 million in Q4 2025, and $72000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 85,464.43 |
| 10 | Pliant Therapeutics | 74.16 Mn | 74.16 Mn | - | 74,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74,000.00 |
| Mar 31, 2026 | 74,000.00 |
| Dec 31, 2025 | -32.27 Mn |
| Dec 31, 2025 | -32.27 Mn |
| Sep 30, 2025 | 72,000.00 |
| Sep 30, 2025 | 72,000.00 |
| Mar 31, 2025 | 498,000.00 |
| Mar 31, 2025 | 498,000.00 |
| Dec 31, 2024 | 102,000.00 |
| Dec 31, 2024 | 102,000.00 |
| Sep 30, 2024 | 543,000.00 |
| Sep 30, 2024 | 543,000.00 |
| Jun 30, 2024 | 684,000.00 |
| Jun 30, 2024 | 684,000.00 |
| Mar 31, 2024 | 21.79 Mn |
| Mar 31, 2024 | 21.79 Mn |
| Dec 31, 2023 | 219,000.00 |
| Dec 31, 2023 | 219,000.00 |
| Sep 30, 2023 | 699,000.00 |
| Sep 30, 2023 | 699,000.00 |